Derm-Biome Pharmaceuticals to develop skincare treatment that promotes skin health and longevity
13 août 2024 10h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy aging, is excited to...
NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
09 août 2024 16h04 HE
|
NurExone Biologic Inc
NurExone announces promising new data for its ExoPTEN nanodrug, highlighting progress towards commercial-grade manufacturing
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
07 août 2024 07h00 HE
|
CytoSorbents
CytoSorbents to Report Q2 2024 Financial and Operating Results
NodThera Named a ‘Fierce 15’ Company by Fierce Biotech
05 août 2024 10h16 HE
|
NodThera
NodThera Named a ‘Fierce 15’ Company by Fierce Biotech Philadelphia, PA, August 5, 2024 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic...
NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer
01 août 2024 07h00 HE
|
NodThera
NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer Greg brings over 25 years of public and private company leadership experience Philadelphia, PA, August 1, 2024 -...
NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk
12 juin 2024 07h00 HE
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk ...
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
31 mai 2024 01h05 HE
|
Regeneron Pharmaceuticals, Inc.
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved...
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
31 mai 2024 01h00 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by...
NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer
28 mai 2024 07h00 HE
|
NodThera
NodThera INC (“NodThera” or the “Company”) NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer Dan joins NodThera with over 30 years of pharmaceutical industry leadership...
Dr. Nooristani Announces Breakthrough Solution for Combatting Acidosis
21 mai 2024 09h00 HE
|
Balance7
Santa Maria , May 21, 2024 (GLOBE NEWSWIRE) -- Are you aware of the silent threat acidosis poses to your health? Acidosis, an imbalance in the body's pH levels, can lead to serious health issues...